Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ic Open-label Study to Evaluate the Pharmacodynamic Effects, Pharmacokinetics, and Safety of Vixarelimab in Patients With Moderate to Severe Active Ulcerative Colitis

NCT06693908 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06693908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06693908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ic Open-label Study to Evaluate the Pharmacodynamic Effects, Pharmacokinetics, and Safety of Vixarelimab in Patients With Moderate to Severe Active Ulcerative Colitis
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2025
Completion date
August 18, 2026
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe ulcerative colitis